Changes in the paper entitled “Study on the Therapeutic Benefit on Lactoferrin in Patients with Colorectal Cancer Receiving Chemotherapy” are as follows:
Title of Table 4 was changed.
Tables 5 and 6 became one table, currently numbered 5, containing updated information compared to the published paper.
Table 4.
Differences between parameters values before treatment and three months after treatment indicate improvement of all parameters after treatment among the studied patients in test group with colorectal cancer receiving chemotherapy and bLF (results represented as mean ± SD values).
| Parameter | Control mean ± SD |
LF mean ± SD |
|---|---|---|
| BUN (mg/dL) | 0.3 ± 2.9 | 4.8 ± 3.14∗ |
| Serum creatinine (mg/dL) | 0.078 ± 0.22 | 0.078 ± 0.22 0.14 ± 0.26∗ |
| AST (IU/L) | 0.306 ± 7.29 | 12.44 ± 13.22∗ |
| ALT (IU/L) | 0.88 ± 5.4 | 6.88 ± 11.27∗ |
| Serum LF (ng/mL) | 0.002 ± 0.011 | 0.15 ± 0.16∗ |
| Serum GST enzyme (ng/mL) | 0.000 ± 0.002 | 0.206 ± 0.089∗ |
| INF-γ (pg/mL) | 0.1 ± 0.27 | 1.62 ± 0.66∗ |
| WBCs (∗103 cell/μL) | 0.146 ± 0.72 | 1.06 ± 1.18∗ |
| Platelet (∗103/mm3) | 25.40 ± 39.06 | 36.46 ± 12.26∗ |
| CEA (ng/mL) | 8.37 ± 23.91 | 13.41 ± 21.91∗ |
| RBCs (∗106/μL) | 0.111 ± 0.222 | 0.514 ± 0.126∗ |
| Neutrophil (%) | 0.93 ± 4.7 | 11.86 ± 1.45∗ |
| Hb (g/dL) | 0.52 ± 1.2 | 1.97 ± 0.35∗ |
Note: ∗significant difference P ≤ 0.05.
Table 5.
Mean percent of change of all parameters after compared to before treatment among the studied patients with colorectal cancer receiving chemotherapy (treated with recombinant human lactoferrin and not).
| Parameter | LF mean ± SD |
Control mean ± SD |
P |
|---|---|---|---|
| Serum LF (%) | 111.17% ± 96.69% | 1.65% ± 5.36% | 0.001∗ |
| Serum GST enzyme (%) | 31.83% ± 19.83% | ↓ −0.26% ± 0.41% | 0.001∗ |
| INF-γ (%) | 5.12% ± 2.18% | ↓ −0.33% ± 0.84% | 0.001∗ |
| CEA (%) | ↓ −47.45% ± 20.91% | 95.92% ± 144.93% | 0.001∗ |
| BUN (%) | ↓ −28.18% ± 10.47% | 7.92% ± 21.44% | 0.0001∗ |
| Serum creatinine (%) | ↓ −5.24% ± 37.15% | 13.03% ± 24.20% | 0.122 |
| AST (%) | ↓ −27.50% ± 15.13% | 4.63% ± 29.46% | 0.001∗ |
| ALT (%) | ↓ −5.66% ± 46.83% | 3.97% ± 15.96% | 0.457 |
| RBCs (%) | 11.65% ± 2.15% | ↓ −2.56% ± 5.06% | 0.0001∗ |
| Hb (%) | 17.91% ± 2.76% | ↓ −3.75% ± 9.53% | 0.0001∗ |
| WBCs (%) | 21.51% ± 18.27% | ↓ −1.40% ± 11.09% | 0.0001∗ |
| Platelet (%) | 18.51% ± 4.56% | ↓ −10.38% ± 14.81% | 0.0001∗ |
| Neutrophil (%) | 26.31% ± 2.11% | ↓ −1.08% ± 9.33% | 0.0001∗ |
Note: ∗significant (P ≤ 0.05).